Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.

ABSTRACT:

Background

Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, adversely affecting patient outcomes.

Methods

We assessed demographics and outcomes for the PWID population in a double-blind trial of 698 patients randomized to dalbavancin 1500 mg as a single intravenous (IV) infusion or as a 2-dose regimen (1000 mg IV on day 1; 500 mg IV on day 8) for ABSSSI. The primary endpoint was ≥20% reduction in erythema at 48-72 hours in the intent-to-treat population; clinical status was also assessed at days 14 and 28.

Results

There were 212/698 (

SUBMITTER: Gonzalez PL 

PROVIDER: S-EPMC6292452 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature